Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Observational × Biguanides × Clear all

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Blood Specimen Collection 25 Data Collection 24 Sorafenib 23 Nivolumab 23 Bevacizumab 21 palbociclib 19 Observation 18 radium Ra 223 dichloride 17 Sunitinib 17 enzalutamide 16 Rituximab 15 Trastuzumab 13 ribociclib 12 regorafenib 12 exemestane 12 atezolizumab 11 Leuprolide 11 Ipilimumab 11 Drug Therapy 11 Docetaxel 11 apalutamide 10 Standard of Care 10 Capecitabine 10 Bortezomib 10 Afatinib 10 Therapeutics 9 Cetuximab 9 Anastrozole 9 Abiraterone Acetate 9 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-02-12

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡